TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12571167

Group type: EXPERIMENTAL
Intervention: rFSH
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: rLH
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: rFSH and rLH (225 IU/day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: rLH (225 IU/day)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: rLH (450 IU/day)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 12088604

Group type: EXPERIMENTAL
Intervention: Guidebook for self-care and doctor/patient interaction
Number of subjects: 136
Study: 9686822

Group type: EXPERIMENTAL
Intervention: rhG‐CSF (10 microg/kg) administered for 3 consecutive days (0, 1, 2)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (no rhG‐CSF)
Number of subjects: 62
Study: 7900230

Group type: EXPERIMENTAL
Intervention: Limited resection
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lobectomy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Limited resection (for tumors > 2.0 cm)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lobectomy (for tumors > 2.0 cm)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Limited resection (for adenocarcinoma)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Lobectomy (for adenocarcinoma)
Number of subjects: 32
Study: 2680679

Group type: EXPERIMENTAL
Intervention: W14859 (liquid thrombin)
Number of subjects: 29
Study: 974460

Group type: EXPERIMENTAL
Intervention: Ge(Li) detector scanner
Number of subjects: 165

Group type: COMPARATOR
Intervention: NaI (Tl) detectors
Number of subjects: 165
Study: 30711917

Group type: EXPERIMENTAL
Intervention: Standard Operating Procedure (SOP) for PCV measurement
Number of subjects: 57

Group type: COMPARATOR
Intervention: No Standard Operating Procedure (No SOP) for PCV measurement
Number of subjects: 57
Study: 28235210

Group type: EXPERIMENTAL
Intervention: Pedometer use
Number of subjects: 130
Study: 25048750

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LDA) 60 mg/d
Number of subjects: 2503

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2503
Study: 24868256

Group type: EXPERIMENTAL
Intervention: Probiotic oral capsules
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Vaginal capsules with probiotics
Number of subjects: 173

Group type: COMPARATOR
Intervention: Classical antibiotic therapy
Number of subjects: 173
Study: 21109462

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion of 0.1 μg/kg/min (Group 1)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Remifentanil infusion of 0.2 μg/kg/min (Group 2)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 60
Study: 19086773

Group type: EXPERIMENTAL
Intervention: 2 mg nicotine gum
Number of subjects: 32

Group type: COMPARATOR
Intervention: 0 mg nicotine gum
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Cigarette abstinence
Number of subjects: 32
Study: 17156425

Group type: EXPERIMENTAL
Intervention: MARS
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Prometheus
Number of subjects: 8
Study: 12627468

Group type: EXPERIMENTAL
Intervention: naloxone (125 microg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 30
Study: 10677394

Group type: EXPERIMENTAL
Intervention: Intravenous administration of high dose (250 mg/250 mg) of lactulose/rhamnose
Number of subjects: 10

Group type: COMPARATOR
Intervention: Intravenous administration of regular dose (50 mg/50 mg) of lactulose/rhamnose
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Intraduodenal administration of lactulose and rhamnose with accelerated small-bowel transit
Number of subjects: 10
Study: 9313390

Group type: EXPERIMENTAL
Intervention: Low intensity weight‐bearing exercise program (thrice‐weekly for 12 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Minimal treatment (education program only)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Low intensity weight‐bearing exercise program
Number of subjects: 30
Study: 8458054

Group type: EXPERIMENTAL
Intervention: Cefadroxil (30 mg/kg once daily for 10 days)
Number of subjects: 462

Group type: COMPARATOR
Intervention: Cephalexin (30 mg/kg/day in two divided doses for 10 days)
Number of subjects: 462
Study: 29443867

Group type: EXPERIMENTAL
Intervention: Whole-Body Vibration (WBV)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Pilates Exercise
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control
Number of subjects: 51
Study: 29728298

Group type: EXPERIMENTAL
Intervention: Kinesio Taping using origin to insertion
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Kinesio Taping using insertion to origin
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control limb (non-dominant limb)
Number of subjects: 42
Study: 27242317

Group type: EXPERIMENTAL
Intervention: Cranberry juice containing 1238 mg total cranberry (poly)phenols
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control drink
Number of subjects: 10
Study: 24051077

Group type: EXPERIMENTAL
Intervention: tailored e‐SBI
Number of subjects: 143

Group type: COMPARATOR
Intervention: time‐matched control condition
Number of subjects: 143
Study: 22980168

Group type: EXPERIMENTAL
Intervention: Apical preparation size enlarged to 2 sizes larger than FABF (Group A)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Apical preparation size enlarged to 3 sizes larger than FABF (Group B)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Apical preparation size enlarged to 4 sizes larger than FABF (Group C)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Apical preparation size enlarged to 5 sizes larger than FABF (Group D)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Apical preparation size enlarged to 6 sizes larger than FABF (Group E)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: All groups (A to E)
Number of subjects: 167
Study: 20180916

Group type: EXPERIMENTAL
Intervention: Biventricular pacing (upgraded from RVAP)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Cardiac resynchronization therapy (CRT) as initial therapy
Number of subjects: 39
Study: 18568272

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 622
Study: 15759527

Group type: EXPERIMENTAL
Intervention: Additional exercise at the weekend provided by nursing staff
Number of subjects: 41

Group type: COMPARATOR
Intervention: Usual care during weekdays and weekend
Number of subjects: 41
Study: 12442560

Group type: EXPERIMENTAL
Intervention: Anonymous assessment
Number of subjects: 358

Group type: COMPARATOR
Intervention: Confidential assessment
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Higher erotophilia
Number of subjects: 358
Study: 10356736

Group type: EXPERIMENTAL
Intervention: Act-Hib vaccine
Number of subjects: 0
Study: 7497560

Group type: EXPERIMENTAL
Intervention: Ranitidine 300 mg with sodium citrate/bicarbonate
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 1770397

Group type: EXPERIMENTAL
Intervention: Aminosyn‐PF
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Troph‐Amine
Number of subjects: 44
Study: 6812106

Group type: EXPERIMENTAL
Intervention: 0.25 mg/kg methylphenidate
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 0.50 mg/kg methylphenidate
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: 1.0 mg/kg methylphenidate
Number of subjects: 25

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study: 31870925

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Number of subjects: 0
Study: 30914065

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Graded Exercise Therapy (GET)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 28763702

Group type: EXPERIMENTAL
Intervention: Wearable vibrotactile biofeedback system (turned on)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control condition (biofeedback system turned off)
Number of subjects: 10
Study: 26166519

Group type: EXPERIMENTAL
Intervention: e.max press all-ceramic onlays
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Metal crowns
Number of subjects: 45

Group type: COMPARATOR
Intervention: Resin (control)
Number of subjects: 45
Study: 22520720

Group type: EXPERIMENTAL
Intervention: Progressive volume deflation (10% of total volume every hour for 5 hours; group V)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Ratio weaning (4 consecutive hours of a 1:2 assisting ratio followed by 1 hour of a 1:3 ratio; group R)
Number of subjects: 30
Study: 22005425

Group type: EXPERIMENTAL
Intervention: Neutered group (neutered at 19 weeks old)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Entire group (kept entire)
Number of subjects: 24
Study: 18692788

Group type: EXPERIMENTAL
Intervention: Luteal phase support with vaginal progesterone gel (Crinone 8% gel)
Number of subjects: 214

Group type: COMPARATOR
Intervention: No luteal phase support
Number of subjects: 214
Study: 17529865

Group type: EXPERIMENTAL
Intervention: Chlorhexidine (0.25%)
Number of subjects: 133

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study: 15595257

Group type: EXPERIMENTAL
Intervention: Hydrogel coated EVD catheters (Bioglide, Medtronic)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Standard silastic EVD catheters
Number of subjects: 158
Study: 11791803

Group type: EXPERIMENTAL
Intervention: Recent depressive episodes
Number of subjects: 750
Study: 9747829

Group type: EXPERIMENTAL
Intervention: Involved field radiation (IF) to 55.8 Gy
Number of subjects: 178

Group type: COMPARATOR
Intervention: Standard whole bone radiation (SF) to 55.8 Gy
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (C/A) followed by radiotherapy
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Surgical patients +/− postoperative radiotherapy
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Localized patients undergoing radiotherapy
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Quality of radiotherapy
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Site of primary tumor
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Patterns of failure
Number of subjects: 178
Study: 7843870

Group type: EXPERIMENTAL
Intervention: Nontraditional distant prayer
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 21
Study: 2896685

Group type: EXPERIMENTAL
Intervention: Disposable humidifying systems ('Conchapak')
Number of subjects: 116

Group type: COMPARATOR
Intervention: Reusable humidifying systems
Number of subjects: 116
Study: 30591616

Group type: EXPERIMENTAL
Intervention: Nurse home visiting (NHV) program (right@home) with 25 nurse visits until child age 2 years
Number of subjects: 722

Group type: EXPERIMENTAL
Intervention: Nurse home visiting (NHV) program (right@home)
Number of subjects: 722
Study: 28219063

Group type: EXPERIMENTAL
Intervention: CSU patients
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 25245190

Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir (300 mg/100 mg) with 0.35 mg norethindrone
Number of subjects: 10

Group type: COMPARATOR
Intervention: Other antiretroviral therapy known to not alter norethindrone levels
Number of subjects: 10
Study: 24126713

Group type: EXPERIMENTAL
Intervention: nebivolol/HCTZ
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: metoprolol/HCTZ
Number of subjects: 22
Study: 22336361

Group type: EXPERIMENTAL
Intervention: Vitamin A
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Vitamin A plus iron
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Multiple micronutrient-fortified seasoning powder (7 + 1)
Number of subjects: 226
Study: 19508744

Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Number of subjects: 20
Study: 16850457

Group type: EXPERIMENTAL
Intervention: FeNO group (n = 22)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (n = 25)
Number of subjects: 47
Study: 16146902

Group type: EXPERIMENTAL
Intervention: Eptifibatide infused during PCI
Number of subjects: 0
Study: 11703958

Group type: EXPERIMENTAL
Intervention: Diet plus statins (simvastatin and pravastatin)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 70
Study: 9394096

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate (TC) 100 mg/wk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate (TC) 250 mg/wk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Testosterone cypionate (TC) 500 mg/wk
Number of subjects: 0

Group type: COMPARATOR
Intervention: Testosterone cypionate (TC) placebo
Number of subjects: 0
Study: 7971536

Group type: COMPARATOR
Intervention: Content only
Number of subjects: 614

Group type: COMPARATOR
Intervention: Content plus supervised practice on a model
Number of subjects: 614

Group type: COMPARATOR
Intervention: Content plus individual instruction on their own breasts
Number of subjects: 614
Study: 3371838

Group type: EXPERIMENTAL
Intervention: Pinaverium bromide (4 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31744959

Group type: EXPERIMENTAL
Intervention: Serum vascular endothelial growth factor (VEGF) assessment
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Clinical biomarker (CB) module
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Clinical module tested on all 250 patients
Number of subjects: 250

Group type: COMPARATOR
Intervention: Comparison with healthy controls
Number of subjects: 250
Study: 28270277

Group type: EXPERIMENTAL
Intervention: Group A (n=14) with CARE kV (100 kV, 214 mA) and sinogram‐affirmed iterative reconstruction
Number of subjects: 27

Group type: COMPARATOR
Intervention: Group B (n=13) with CARE kV (100 kV, 171 mA) and advanced modeled iterative reconstruction
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 27
Study: 26900641

Group type: EXPERIMENTAL
Intervention: Metformin 850 mg twice daily
Number of subjects: 2155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2155
Study: 24763155

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Yoga
Number of subjects: 30
Study: 22382604

Group type: EXPERIMENTAL
Intervention: Early MRI within 2 weeks
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional management with physiotherapy
Number of subjects: 46
Study: 19171641

Group type: EXPERIMENTAL
Intervention: Sleep-deprived electroencephalogram
Number of subjects: 206

Group type: COMPARATOR
Intervention: Routine electroencephalogram
Number of subjects: 206
Study: 17506222

Group type: EXPERIMENTAL
Intervention: Serotonin reuptake inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 14766687

Group type: EXPERIMENTAL
Intervention: Clear ocular hydro-gel (Vidisic)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Ocular dexpanthenol ointment (Oleovit)
Number of subjects: 92
Study: 12390061

Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin (reviparin sodium, 4200 anti-Xa IU)
Number of subjects: 1279

Group type: COMPARATOR
Intervention: Oral anticoagulant (acenocoumarol, INR 2-3)
Number of subjects: 1279
Study: 9922426

Group type: EXPERIMENTAL
Intervention: Phosphacap cement
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fuji Cap I cement
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Panavia 21 cement
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Coarse diamonds
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Fine diamonds
Number of subjects: 10
Study: 7547378

Group type: EXPERIMENTAL
Intervention: Acetazolamide therapy
Number of subjects: 122

Group type: COMPARATOR
Intervention: Control therapies
Number of subjects: 122
Study: 2232659

Group type: EXPERIMENTAL
Intervention: anapriline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: corinfar
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: reserpine
Number of subjects: 60
Study: 387619

Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Gentamicin
Number of subjects: 50
Study: 31956924

Group type: COMPARATOR
Intervention: 4 kg/head/day concentrate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 5 kg/head/day concentrate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 6 kg/head/day concentrate
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 7 kg/head/day concentrate
Number of subjects: 40
Study: 31120950

Group type: EXPERIMENTAL
Intervention: Diversification of portfolios during the crisis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Similarity of investments of different funds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overlap of investments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic risk component from portfolio similarity
Number of subjects: 0
Study: 28322128

Group type: EXPERIMENTAL
Intervention: HHQ-reduced coffee
Number of subjects: 0

Group type: COMPARATOR
Intervention: HHQ-containing coffee
Number of subjects: 0
Study: 25867124

Group type: EXPERIMENTAL
Intervention: Tapentadol ER
Number of subjects: 946

Group type: EXPERIMENTAL
Intervention: Oxycodone CR
Number of subjects: 946

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 946
Study: 25098611

Group type: EXPERIMENTAL
Intervention: EUS-FNB using a core biopsy needle
Number of subjects: 116

Group type: COMPARATOR
Intervention: EUS-FNA using a standard aspiration needle
Number of subjects: 116
Study: 21842158

Group type: EXPERIMENTAL
Intervention: Moderate dose (0.5 g/l)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High dose (1 g/l)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo dose (0 g/l)
Number of subjects: 0
Study: 19637645

Group type: EXPERIMENTAL
Intervention: New softening agent formulations (non-ionic surfactants or non-toxic ingredients)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available phenol-based formulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New softening agent formulations
Number of subjects: 0
Study: 17875971

Group type: EXPERIMENTAL
Intervention: MECC
Number of subjects: 150

Group type: COMPARATOR
Intervention: OPCABG
Number of subjects: 150
Study: 15356087

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ghrelin (0.25 microg/kg body weight) + Atropine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ghrelin (1 microg/kg body weight) + Atropine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ghrelin (0.25 microg/kg body weight) + Pyridostigmine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ghrelin (1 microg/kg body weight) + Pyridostigmine
Number of subjects: 12
Study: 11255933

Group type: EXPERIMENTAL
Intervention: Combined pharmacological and behavioral treatments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-help materials only
Number of subjects: 0
Study: 9738781

Group type: EXPERIMENTAL
Intervention: Calcipotriene ointment on weekdays and halobetasol ointment on weekends
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo ointment on weekdays and halobetasol ointment on weekends
Number of subjects: 44
Study: 7993168

Group type: EXPERIMENTAL
Intervention: Blue identification bracelet
Number of subjects: 134

Group type: COMPARATOR
Intervention: No bracelet (Control)
Number of subjects: 134
Study: 2223935

Group type: EXPERIMENTAL
Intervention: Pre-exposure to to-be-CSs
Number of subjects: 64

Group type: COMPARATOR
Intervention: Fear-relevant stimuli
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Short rest period before acquisition
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Extended rest period before acquisition
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Differential conditioning
Number of subjects: 64
Study: 320478

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 10 mg with morphine
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Dextroamphetamine 5 mg with morphine
Number of subjects: 450

Group type: COMPARATOR
Intervention: Morphine alone (3, 6 or 12 mg)
Number of subjects: 450
Study: 31388790

Group type: EXPERIMENTAL
Intervention: Balloon dissection (BD)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Telescopic dissection (TD)
Number of subjects: 40
Study: 28140641

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Physical rehabilitation with sham photobiomodulation treatment
Number of subjects: 32

Group type: COMPARATOR
Intervention: Sham photobiomodulation treatment only
Number of subjects: 32
Study: 26166378

Group type: EXPERIMENTAL
Intervention: Oral oxycodone (5 mg)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Oral naproxen (250 mg)
Number of subjects: 150
Study: 23403073

Group type: EXPERIMENTAL
Intervention: Motivational interviewing and positive affect and self-affirmation strategies
Number of subjects: 220
Study: 21727006

Group type: EXPERIMENTAL
Intervention: Ibandronate 6 mg infused over 15 min
Number of subjects: 334

Group type: COMPARATOR
Intervention: Ibandronate 6 mg infused over 60 min
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Ibandronate 6 mg infused over 15 min and 60 min
Number of subjects: 334
Study: 19803123

Group type: EXPERIMENTAL
Intervention: Lidocaine 1%
Number of subjects: 150

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 150
Study: 18681089

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.1%
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Olopatadine 0.2%
Number of subjects: 20

Group type: COMPARATOR
Intervention: Azelastine 0.1%
Number of subjects: 20
Study: 15466605

Group type: EXPERIMENTAL
Intervention: Implicit ethnocentrism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Explicit ethnocentrism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Implicit and explicit attitudes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Latent variable modeling
Number of subjects: 0
Study: 11506105

Group type: EXPERIMENTAL
Intervention: Acupuncture (intradermal needles inserted at acupoints 2.5 cm from the spinal vertebrae)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 175
Study: 10065907

Group type: EXPERIMENTAL
Intervention: Oxazepam (30 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60